Cutler Group LP Vaxart, Inc. Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$0.75 - $2.24 $330 - $987	-441 Reduced 46.87%	500 $0
Q3 2022 Oct 25, 2022	SELL	$2.09 - $4.5 $15,616 - $33,624	-7,472 Reduced 88.81%	941 $2,000
Q2 2022 Aug 04, 2022	BUY	$2.7 - $5.28 $7,290 - $14,256	2,700 Added 47.26%	8,413 $29,000
Q1 2022 Apr 14, 2022	BUY	$4.29 - $6.64 $7,563 - $11,706	1,763 Added 44.63%	5,713 $28,000
Q4 2021 Jan 18, 2022	BUY	$5.77 - $7.96 $4,616 - $6,368	800 Added 25.4%	3,950 $24,000
Q3 2021 Oct 26, 2021	SELL	$6.67 - $9.8 $34,443 - $50,607	-5,164 Reduced 62.11%	3,150 $25,000
Q2 2021 Jul 19, 2021	BUY	$5.06 - $10.78 $11,309 - $24,093	2,235 Added 36.77%	8,314 $62,000
Q1 2021 Apr 26, 2021	SELL	$5.64 - $23.33 $19,192 - $79,391	-3,403 Reduced 35.89%	6,079 $36,000
Q4 2020 Jan 21, 2021	SELL	$3.5 - $7.98 $44,821 - $102,191	-12,806 Reduced 57.46%	9,482 $54,000
Q3 2020 Oct 27, 2020	BUY	$4.78 - $16.97 $106,536 - $378,227	22,288 New	22,288 $148,000

108

37.9M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $93.6M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.